ATO: the forefront of APL treatment? ----------------------------------------------------------------------------------------------------------------Dan Douer UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Arsenic trioxide (ATO) is the standard induction treatment of relapsed acute promyelocytic leukemia (APL). 1 Now Mathews and colleagues from India show that single-agent ATO can induce and maintain a molecular remission in patients with newly diagnosed APL.
S
everal large randomized and nonrandomized trials established the combination of all-trans retinoic acid (ATRA) plus chemotherapy as the standard treatment for newly diagnosed APL, curing most of the patients. 2 The high complete remission (CR) rate with ATO in relapsed APL led to its investigation in newly diagnosed patients. In fact, more than a decade ago investigators in China reported that single-agent ATO is effective in such patients. 3 The studies were also supported by the observation that ATO is more efficient than ATRA in reducing the degree of minimal residual APL cells. In newly diagnosed patients, ATRA as a single agent induces hematologic complete remission (CR) in almost all patients, but very often fails to produce molecular remissions. In contrast, ATO induces molecular remission in almost all patients treated at relapse. Further, a study from study China showed, using quantitative polymerase chain reaction (PCR), that the number of PML/ RAR␣ transcript copies was significantly lower after induction treatment with ATO than with ATRA in a small group of newly diagnosed patients. 4 ATO is being studied in newly diagnosed APL patients in 2 ways. One approach is adding ATO to the standard ATRA/chemotherapy regimen to improve the overall outcome. A small randomized trial from China suggested that the combination of all 3 modalities-chemotherapy, ATRA, and ATO in different treatment phases-resulted in significantly better outcome than chemotherapy plus ATRA. 4 A much larger U.S. intergroup randomized trial studied whether adding 2 cycles of ATO consolidations to standard ATRA/chemotherapy would improve the overall outcome, but the results are pending. The second approach is that ATO may allow reducing or even eliminating chemotherapy and perhaps even ATRA, lowering the toxicity while maintaining the excellent outcome. Such an approach was taken by Matthew and colleagues using ATO as a single agent, and the results are reported in this issue.
Not surprisingly, ATO induced in 72 newly diagnosed patients a complete remission (CR) rate of 86% (although a minority of 8 patients received anthracycline for high white cell count), without evidence of disease resistance. Similar results were reported by a group in Iran. 5 Prior to the next treatment cycle, most (76%) of the studied CR patients were PCR negative for PML/RAR␣. However, of greater interest is that ATO alone, given as consolidation plus maintenance of 10 doses per month for 6 cycles, was very effective in maintaining the molecular remission. The 3-year event-free survival was 75%. Further, using the white cell and platelet count at diagnosis, Mathews et al identified 2 risk groups that are different from those reported by Sanz et al. 6 All 20 patients in the good-risk group were alive and in remission (see figure) .
Although this approach is less toxic and the results are promising, single-agent ATO cannot yet be considered an alternative to wellstudied standard APL treatment: the number of patients is much smaller and the duration of follow-up is relatively shorter than those studied with ATRA plus chemotherapy. Also, the outcome of those not considered good-risk patients may not be as positive as in the poorand intermediate-risk patients classified by the criteria of Sanz et al 2 despite the difficulty in a direct comparison (see figure) .
An advantage of single-agent ATO was its limited toxicity, especially infrequent and very short occurrence of grade 3/4 neutropenia. However, this is probably gained by eliminating the intensive chemotherapy, raising the question of whether ATRA also needs to be avoided. One might be concerned with using a single agent in a disease that is already highly curable. In fact, synergism between ATO and ATRA was demonstrated in APL animal models. Further, in newly diagnosed APL patients, minimal residual disease measured by quantitative PCR was significantly lower with ATRA plus ATO induction than with ATO alone. 4 A smaller study showed a very high percentage of continued molecular remission even in high-risk patients with ATRA plus ATO, with the addition of gemtuzumab only for high-risk patients. 7 Taken together, replacing standard chemotherapy with ATO in newly diagnosed
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APL will require larger studies. However, for selected patients who cannot tolerate anthracycline-for example those with cardiac dysfunction, older adults with poor performance status, and possibly Jehovah's Witnesses-ATO (probably still in combination with ATRA) would be a very reasonable alternative to the standard ATRA/chemotherapy. Of interest, in this report, patients were initially enrolled in the study because they could not afford standard therapy since the cost of single-agent ATO was much lower. In countries where cost would prohibit standard treatment of APL, a cheaper ATO, produced under good quality control, would be effective in curing many APL patients.
The optimal use of ATO in newly diagnosed APL patients still needs to be established. Regardless, this study demonstrates that ATO is a very active-perhaps even the most active-single agent for treating APL. ■ -------------------------------------------------------------------------------------------------------------- C hronic graft-versus-host disease (cGVHD) is a major cause of long-term nonrelapse morbidity and mortality in patients who undergo an allogeneic hematopoietic cell transplantation (HCT). 1 cGVHD classically arises more than 100 days and rarely later than 500 days after transplantation. It presents as a progressive clinical syndrome that can involve multiple organs. Features of cGVHD resemble certain autoimmune diseases such as progressive systemic sclerosis, systemic lupus erythematosus, and others. Among the target organs commonly involved are the skin, liver, eyes, and/or oral pharynx. cGVHD can be treated with immunosuppression, and the mainstay of therapy is corticosteroids. However, despite immunosuppressive treatment, approximately 20% to 50% of patients who develop cGVHD die from complications associated with this disease. 1 The pathophysiology of cGVHD is poorly understood. Donor T cells are thought to be the principal cause of both forms of GVHDacute and chronic. However, different target antigens and effector pathways seem to mediate these clinical syndromes. Whereas acute GVHD is triggered by alloantigens recognized by T cells that mature in the thymus of the donor, the pathologic process of cGVHD is less certain. It has not yet been determined if donor postthymic or de novo graft-derived T cells predominate in this aberrant immune response. Whether the inciting antigens represent different allelic forms of donor and recipient molecules (alloantigens) or nonallelic endogenous molecules (autoantigens) is also not known. Recent clinical studies have shown that antibody responses against documented allogeneic targets correlate with the development and severity of cGVHD. 2 Since alloantibodies are not thought to play a role in acute GVHD, these data further suggest that distinct pathologies underlie these syndromes.
Few animal models exist for the study of cGVHD. Some of the best-studied models use strain combinations that differ at the mouse major histocompatibility complex (MHC) equivalent of the human HLA, called H-2. 3, 4 In humans, HLA disparities certainly increase the likelihood of developing cGVHD. However, approximately 40% of recipients of HLA-matched sibling grafts develop the syndrome. Thus, in the search for ways to accurately model the cGVHD syndrome, investigators are now more frequently turning to the use of donor/recipient strain combinations that are matched at H-2 but differ at other genetic loci (minor alloantigens). 5 In this issue of Blood, Zhang and colleagues report on the development of a new mouse model of cGVHD. The novelty of the model is based on the investigators' use of a donor/ recipient pair that has not been previously reported, and disease is induced in recipients given the equivalent of a mouse nonmyeloablative transplant. DBA/2 and BALB/c mice are matched at H-2 but have multiple minor antigenic differences. When sublethally irradiated BALB/c mice receive transplants of large numbers of DBA/2 spleen cells (which contain progenitor and mature immune cells), the mice develop a syndrome with features resembling human cGVHD within 20 to 50 days after HCT. These features include sclerodermatous skin changes (more pronounced than in an existing model) and lupuslike abnormalities including serum antibodies to doublestranded DNA and glomerulonephritis. Removal of the thymus in some recipients did not change disease outcome, suggesting that donor postthymic T cells cause this syndrome. More importantly, Zhang et al show that mature donor B lymphocytes and not de novo B cells that arise after transplantation are associated with disease development. The investigators also address the role of donor T-cell subsets in mediating disease, including the activities of regulatory CD4 ϩ CD25 ϩ cells. Development of cGVHD in this model is dependent upon CD4 ϩ and not CD8 ϩ T cells, and CD4 ϩ CD25 Ϫ cells are required for cGVHD induction, whereas CD4 ϩ CD25 ϩ cells suppress the disease.
This newly established mouse model, which shares important features with the human syndrome, is certainly a welcomed addition to the armamentarium against cGVHD. 
